8-K filing — Alector, Inc. (ALEC)
Filed: 2026-10-16 AccNo: 0001193125-26-424204 Size: 423 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Alector Teams Up With Genentech On Potential Parkinson’s Treatment
Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alector Prices $75.03M Common Stock Offering Of 36.6M Shares At $2.05/Share
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $5 to $8.